LACTULOSE
High-risk Prostate Cancer
Assistance Publique - Hôpitaux de ParisSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the High-risk Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etbx-071 ImmunityBio, Inc. | Phase 2 | CCC |
MEMORY CYTOKINE-ENHANCED NK CELLS ImmunityBio, Inc. | Phase 2 | CCC |
Fk-Pc101 Cellvax Therapeutics Inc | Phase 2 | CCC |
Adv/Hsv-Tk The Methodist Hospital Research Institute | Phase 2 | CCC |
Famitinib Fudan University | Phase 2 | CCC |
n-803 National Cancer Institute (NCI) | Phase 2 | CCC |
Sucralose Assistance Publique - Hôpitaux de Paris | D | |
MANNITOL Assistance Publique - Hôpitaux de Paris | D |
Same molecule, other indications
LACTULOSE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →